IPP Bureau
Cipla receives EUA for Cipmolnu
By IPP Bureau - December 28, 2021
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
Sun Pharma receives DCGI approval for Molxvir in India
By IPP Bureau - December 28, 2021
The product is expected to be available in a week’s time
India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
By IPP Bureau - December 28, 2021
It plans to deliver over 300 million doses to the Indian government
NATCO receives approval for the drug for the treatment of Covid-19
By IPP Bureau - December 28, 2021
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
Torrent Pharma to launch molnupiravir under the brand name Molnutor in India
By IPP Bureau - December 28, 2021
DCGI approved the drug based on the review of clinical data
Strides to market molnupiravir under the brand name Stripiravir
By IPP Bureau - December 28, 2021
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Dr Reddy’s receives Emergency Use Authorisation for molnupiravir
By IPP Bureau - December 28, 2021
The company will market it under the brand name Molflu
Aurobindo to manufacture and market molnupiravir
By IPP Bureau - December 28, 2021
The drug will be marketed under the brand name Molnaflu
Optimus Pharma to manufacture and market molnupiravir
By IPP Bureau - December 28, 2021
The company has developed the API in house at its R&D center in Hyderabad
Covaxin receives approval for Emergency Use in Children 12-18 years
By IPP Bureau - December 27, 2021
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Lupin receives U.S. FDA approval for Sevelamer Carbonate
By IPP Bureau - December 27, 2021
This product will be manufactured at Lupin's Goa facility in India
Roche gets U.S. FDA nod for at-home Covid-19 self-testing solution
By IPP Bureau - December 27, 2021
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Healthcare start-up Zorgers raises angel round
By IPP Bureau - December 27, 2021
The Home Healthcare market is expected to be US $ 14.2 by 2025
U.S. FDA issues Emergency Use Authorisation for Merck’s molnupiravir
By IPP Bureau - December 24, 2021
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Indian Pharmaceutical Market grew at 6.6 pc in November
By IPP Bureau - December 24, 2021
Flattish volume growth and subdued new launches were key factors for last month
